Ob/Gyn Medical News about Breast Neoplasms Genes, erbB-2

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Targeting HER2 in breast cancer: overview of long-term experience
International Journal of Women's Health, 10/20/09

Lantz E et al. – The ability to probe diseases at the genomic level has improved our understanding and enhanced the treatment of breast cancer. One important finding relates to the HER2 oncogene which encodes a novel transmembrane receptor that, when overexpressed, appears to confer growth and survival advantages to breast tumor cells. This fortuitous discovery enabled researchers to develop agents which could inhibit receptor–mediated tumor cell signaling. Numerous clinical trials of such agents have demonstrated improved outcomes in patients with HER2–positive breast cancer. Nonetheless, not all tumors respond to therapy targeting the receptor, while relapses occur after an initial response to treatment. This paper provides a historical and current perspective of the treatment of patients with HER2–positive breast cancer.

<< Previous
Activating T regulatory cells for tolerance in early pregnancy —...

Next >>
Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in...